Abstract Objective Delivery of the stromal cell-derived cytokine IL-33 protects allografts from rejection by acting on CD11c+ DC that facilitate the expansion of regulatory T cells (Treg). IL-33 administration also permits tolerance induction at doses of co-stimulatory blockade that fails on their own. Based on these data we hypothesized that IL-33-stimulated DC represent a tolerogenic DC subset and their precise examination will define biochemical pathways that contribute to tolerogenic DC functions. Methods Mouse bone marrow-derived CD11c+ DCs were treated with lipopolysaccharide (LPS) or IL-33 before nitric oxide (NO) generation, glucose and fatty acid uptake, and mitochondrial function and potential were assessed by EPR spectroscopy, flow cytometry, and Seahorse analysis. Results DC responded to the TLR4 ligand LPS by generating high levels of NO and shifting their metabolic activity to aerobic glycolysis. This was in stark contrast to IL-33, which caused a metabolic reprogramming in DC that involved augmented mitochondrial basal respiration, ATP production, and maximum respiration. IL-33-stimulated DC also displayed increase mitochondrial potential and a profound increase in the uptake of fatty acids. Conclusions It has emerged that immunogenic DCs undergo metabolic changes that enables their pro-inflammatory functions. The metabolic underpinnings of tolerogenic DCs is less understood. Here we show that IL-33-stimulated DC, which potently expand Treg, rely on oxidative phosphorylation and uptake fatty acids. These data suggest IL-33 initiates metabolic reprogramming matching those found in regulatory myeloid populations, including tumor associated DC and alternatively activated macrophages.